Vertex Pharmaceuticals

NASDAQ: VRTX
$230.29
+$13.05 (+6.0%)
Real time price as of March 30, 2020 1:33 pm EDT
Companies like IBM, Amazon, Western Digital and EA all posted big moves, some far more than what was expected, in Thursday's after-hours trading session for January 30, 2020.
Jon C. Ogg
Why Credit Suisse believes that this round of quarterly biotech earnings could prove to be a catalyst for 2020.
Chris Lange
Monday's top analyst upgrades, downgrades and initiations included Adobe, Amgen, Bank of America, Broadcom, CME, Goldman Sachs, Micron Technology, PepsiCo, UnitedHealth, Urban Outfitters and Vertex...
Jon C. Ogg
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox.
Jon C. Ogg
Tuesday's the top analyst upgrades, downgrades and initiations included Dropbox, Electronic Arts, Halliburton, Intuit, Juniper Networks, ProLogis, Silicon Motion, Taiwan Semiconductor, Textron and...
Jon C. Ogg
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Jon C. Ogg
Friday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Alphabet, Altria, Amazon.com, Boeing, Caterpillar, Chipotle Mexican Grill, E*Trade, Gap, Snap and Twitter.
Jon C. Ogg
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
Jon C. Ogg
These four stocks make good sense now, as they all have outstanding upside potential and are among the Jefferies top U.S. growth calls for this week.
Lee Jackson
On top of the company announcing an acquisition on Tuesday, Vertex has seen a substantial analyst upgrade from Goldman Sachs.
Jon C. Ogg
Here are three biotech stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross, plus two that went the other way.
Trey Thoelcke
Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
Jon C. Ogg
24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some of these analyst reports cover stocks to buy, while others cover...
Chris Lange
CRISPR Therapeutics shares jumped on Tuesday after the firm announced that the FDA has granted Fast Track Designation for its treatment for transfusion-dependent beta thalassemia.
Chris Lange
The top analyst upgrades, downgrades and initiations seen on Tuesday included Alcoa, Apple, Autodesk, BB&T, Bed Bath & Beyond, Camping World, Nvidia, Vertex Pharmaceuticals and Voya Financial.
Jon C. Ogg